Androgen receptors in hormone-dependent and castration-resistant prostate cancer
The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Until recently, chemotherapy for treatment of CRPC was the only modality to demonstrate a survival benefit in a phase III clinical trial (Tannock et al., 2004; Berthold et al., 2008), supporting the FDA approval of docetaxel for patients with CRPC.”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Although the mechanism of action has not been elucidated, adding ADT may enhance radiation effects via increased tumor oxygenation (Zietman et al., 1997a; Zietman et al., 1997b; Kaminski et al., 2003; Jain, 2005; Stewart et al., 2011) and also by preventing dissemination of micro-metastatic disease.”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 2×
“…p b 0.001), time to PSA progression (10.2 vs 6.6 months, p b 0.001), PSA response rate (29% vs 6%, p b 0.001) and overall survival (14.8 vs 10.9 months, p b 0.001), compared to the placebo arm, providing a new option for this group of patients who are difficult to treat (De Bono et al., 2011).”
BackgroundInfluentialRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796 · cited 1×
“Efficacy of AA has also been shown in patients prior to chemotherapy (Ryan et al., 2013).”
BackgroundScreening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 2×
“…well as to substitute for some of the actions of AR. Studies in preclinical models have suggested that increased signaling of multiple growth factor, cytokine, and kinase pathways increase AR signaling facilitating progression to castration resistance (Culig et al., 2000; Feldman & Feldman, 2001).”
Background
Cited by
The role of vitamin D in reducing cancer risk and progression
Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E., & Feldman, B. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3691 · Cited by 1,311
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Role of Androgen Receptor in Prostate Cancer: A Review
Fujita, K., & Nonomura, N. (2019) · The World Journal of Men's Health · doi:10.5534/wjmh.180040 · Cited by 483
“AR-V567es has exons 5–7 spliced out and only contains a small portion of the LBD [12].”
BackgroundInfluentialBarnard, M., Quanson, J. L., Mostaghel, E., Pretorius, E., Snoep, J. L., & Storbeck, K.-H. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.06.013 · Cited by 72
Morell, C., Bort, A., Vara-Ciruelos, D., Ramos-Torres, Á., Altamirano-Dimas, M., Díaz-Laviada, I., & Rodríguez-Henche, N. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162977 · Cited by 50
Metadata
- Authors
- Shafi, A. A., Yen, A. E., & Weigel, N. L.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 140
- Issue
- 3
- Pages
- 223-238
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2036274810
- Cited by
- 420
- References
- 216
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.